Friday, 6 November 2026European Markets

WERELDHAVE BELGIUM And ALTAREA Have A High Dividend Yield And Return On Equity In The Real Estate Sector.

Loading stream...

(vianews) - wereldhave belgium (wehb.br) is among this list of stock assets with the highest dividend rate and return on equity on the real estate sector.

financial asset price forward dividend yield return on equity
wereldhave belgium (wehb.br) €48.00 8.71% 8.05%
altarea (alta.pa) €119.80 7.65% 12.37%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. wereldhave belgium (wehb.br)

8.71% forward dividend yield and 8.05% return on equity

wereldhave belgium is a public regulated real estate company with a focus on commercial property in belgium. wereldhave belgium targets its new investments on shopping centres. the value of the real estate portfolio, including project developments, amounted to € 921.2 mln on 31 december 2020. on 31 december 2020 the existing operational retail portfolio amounted to € 817.8 mln (around 90% of the total portfolio) and it includes shopping centres in liège, nivelles, tournai, genk and kortrijk and retail parks in brugge, ghent, turnhout, waterloo and tournai. in addition, the portfolio of real estate investments includes offices in vilvoorde and antwerp. as of 31 december 2020 the development portfolio of € 12.6 mln contained land holdings and realised investments that relate to the refurbishment and/or expansion of shopping centres in waterloo and liège.

earnings per share

as for profitability, wereldhave belgium has a trailing twelve months eps of €6.23.

pe ratio

wereldhave belgium has a trailing twelve months price to earnings ratio of 7.7. meaning, the purchaser of the share is investing €7.7 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 8.05%.

yearly top and bottom value

wereldhave belgium's stock is valued at €48.00 at 22:30 est, way below its 52-week high of €57.20 and way higher than its 52-week low of €42.80.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on apr 17, 2023, the estimated forward annual dividend rate is 4.2 and the estimated forward annual dividend yield is 8.71%.

more news about wereldhave belgium.

2. altarea (alta.pa)

7.65% forward dividend yield and 12.37% return on equity

altarea is the leading property developer in france. as both a developer and an investor, the group operates in the three main property markets (retail, residential and business property), leading major mixed-use urban renewal projects in france. the group has the required expertise in each sector to design, develop, market and manage made-to-measure property products. listed in compartment a of euronext paris.

earnings per share

as for profitability, altarea has a trailing twelve months eps of €15.82.

pe ratio

altarea has a trailing twelve months price to earnings ratio of 7.57. meaning, the purchaser of the share is investing €7.57 for every euro of annual earnings.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.37%.

yearly top and bottom value

altarea's stock is valued at €119.80 at 22:30 est, way under its 52-week high of €158.20 and higher than its 52-week low of €115.40.

dividend yield

as maintained by morningstar, inc., the next dividend payment is on may 30, 2022, the estimated forward annual dividend rate is 9.75 and the estimated forward annual dividend yield is 7.65%.

moving average

altarea's worth is below its 50-day moving average of €126.19 and under its 200-day moving average of €131.61.

more news about altarea.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com